Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Med Sci Monit ; 25: 5306-5311, 2019 Jul 17.
Artigo em Inglês | MEDLINE | ID: mdl-31313754

RESUMO

BACKGROUND The relationships between culprit coronary plaque characteristics and hyperhomocysteinemia (HHcy) are not fully understood in young patients. In this study we investigated the relationship between culprit atherosclerotic plaque phenotype assessed by optical coherence tomography (OCT) and hyperhomocysteinemia (HHcy) in young patients. MATERIAL AND METHODS We investigated the OCT imaging and HHcy of 123 lesions in 123 young patients (≤45 years of age). According to OCT images, culprit lesions were classified as thin-cap fiber atheroma (TCFA), thrombus, and other. The 123 patients were grouped as: HHcy group (53 cases, HHcy ≥15.5 µmol/l) and control group (70 cases, HHcy <15.5 µmol/l). RESULTS Compared with the control group, the HHcy group had a higher proportion of OCT-TCFA (p=0.03), OCT-vasa vasorum (p=0.013), and OCT-thrombus (p=0.012), and a larger lipid arc (p=0.002). HHcy (P=0.037) and metabolic syndrome (MetS) (P=0.016) remained independent predictors of TCFAs. HHcy (P=0.026) and smoking (P=0.005) remained independent determinants of thrombus. CONCLUSIONS HHcy and MetS are associated with TCFAs, and HHcy and smoking are associated with thrombus in young patients with coronary artery disease.


Assuntos
Doença da Artéria Coronariana/complicações , Hiper-Homocisteinemia/fisiopatologia , Placa Aterosclerótica/patologia , Síndrome Coronariana Aguda/complicações , Adulto , China , Angiografia Coronária/métodos , Doença da Artéria Coronariana/etiologia , Vasos Coronários/patologia , Feminino , Humanos , Hiper-Homocisteinemia/complicações , Masculino , Sobrepeso , Placa Aterosclerótica/metabolismo , Valor Preditivo dos Testes , Estudos Retrospectivos , Fumar , Tomografia de Coerência Óptica/métodos
3.
Chin Med J (Engl) ; 125(19): 3398-403, 2012 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23044295

RESUMO

BACKGROUND: Restenosis of bare-metal stents (BMS) and drug-eluting stents (DES) has been increasingly treated with sirolimus-eluting stents (SES), but the long-term outcomes are unknown. METHODS: In our study, 388 consecutive patients (144 DES restenosis and 244 BMS restenosis) with 400 lesions (147 DES restenosis and 253 BMS restenosis) treated with SES were included. The rates of target lesion revascularization (TLR) and major adverse cardiac events (MACE) at 42 months were analyzed. RESULTS: At the mean follow-up of 42 months, the rates of death (3.5% vs. 3.3%, P = 1.000) and myocardial infarction (2.8% vs. 1.2%, P = 0.431) in the DES group and BMS group were comparable. Compared with the BMS group, ischemia-driven TLR occurred with a higher frequency in the DES group (18.8% vs. 10.7%, P = 0.024). This translated into an increased rate of MACE in the DES group (22.2% vs. 14.0%, P = 0.034). Stent thrombosis occurred with a similar frequency in both groups (2.8% vs. 1.6%, P = 0.475). Multivariate analysis showed that DES restenosis (OR = 1.907, 95%CI 1.108 - 3.285, P = 0.020) and smoking (OR = 2.069; 95%CI 1.188 - 3.605; P = 0.010) were independent predictors of MACE. CONCLUSIONS: Although SES implantation appears to be safe and effective, it was associated with higher TLR recurrence for DES than BMS restenosis.


Assuntos
Reestenose Coronária/induzido quimicamente , Reestenose Coronária/terapia , Stents Farmacológicos/efeitos adversos , Sirolimo/uso terapêutico , Stents/efeitos adversos , Idoso , Angiografia Coronária , Reestenose Coronária/diagnóstico por imagem , Feminino , Humanos , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA